Galapagos
Biotechnology - Innovative Medicines Development
- Has physical offices
- Publicly traded
About Galapagos
A biotechnology company dedicated to developing innovative medicines targeting diseases with high unmet needs, specializing in immunology and oncology
Key facts
- Industry
- Biotechnology Research
- Company size
- 251–1,000 employees
- Headquarters
- Mechelen, Flanders, Belgium
- Founded
- 1999
- Revenue
- €1.1BFY2025, publicly reported
- Website
- glpg.com
- linkedin.com/company/glpg
Galapagos in the news
- Galapagos kondigt intentie aan om celtherapieactiviteiten af te bouwen
Galapagos intends to wind down its cell therapy division, cutting 365 jobs and closing multiple sites to focus on sustainable growth.
- Galapagos vernieuwt raad van bestuur en versterkt strategische focus op business development
Galapagos reorganizes its Board to enhance focus on business development and innovative drug pipeline expansion.
- Galapagos presenteert nieuwe onderzoeksgegevens
Galapagos will present new Phase 3 data on its selective TYK2 inhibitor GLPG3667 for autoimmune diseases at a major rheumatology conference.
- Biotechbedrijf Galapagos wil celtherapieactiviteiten afbouwen: 50 banen bedreigd in Mechelen
Galapagos is scaling back its cell therapy operations, risking 50 jobs, and reconsidering its strategic approach after shelving a planned company split.
- Vooruitgang bij Galapagos
Galapagos is progressing in selling its cell therapy unit, aiming to focus on advanced projects aligned with Gilead's priorities, with a decision expected by early November.
Galapagos at a glance
Galapagos is a company in the Biotechnology Research industry, headquartered in Mechelen, Flanders, Belgium.
Galapagos was founded in 1999.
Galapagos has 251–1,000 employees.
Galapagos's revenue is €1.1B (FY2025, publicly reported).
Selling to companies like Galapagos?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies